Evolving concepts of pharmaceutical company-sponsored surveillance studies

Clinical Infectious Diseases

Volumn 41, Issue 4 SUPPL., 2005, Pages

  Koeth, Laura M ^a   Miller, Linda A ^b  

^a Laboratory Specialists Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFACLOR; CEFIXIME; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; DILUTION; DRUG INDUSTRY; GOVERNMENT; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEALTH SURVEY; HUMAN; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; QUALITY CONTROL; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA; BACTERIAL INFECTIONS; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HUMANS; INTERNATIONAL COOPERATION; POPULATION SURVEILLANCE; RESEARCH; WORLD HEALTH;

EID: 23244434396     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430791     Document Type: Review

References (13)

1. Cornaglia G, Hryniewicz W, Jarlier V, et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10:349-83.
2. Finch R. Antibiotic resistance - from pathogen to disease surveillance. Clin Microbiol Infect 2002; 8:317-20.
3. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50(Suppl 1):1-7.
4. Jacobs MR. Assessing the quality of the Alexander Project. J Chemother 1999; 11(Suppl 1):22-5.
5. Jacobs MR, Felmingham D, Appelbaum P, Grüneberg R, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52:229-46.
6. Felmingham D, Grüneberg R. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45:191-203.
7. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - finding of the Alexander Project 1992-1996. J Chemother 1999; 11(Suppl 1):5-21.
8. Grüneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25:169-81.
9. Poupard J, Brown J, Gagnon R, Stanhope M, Stewart C. Methods for data mining from large multinational surveillance studies. Antimicrob Agents Chemother 2002; 46:2409-19.
10. Jones ME, Blosser-Middleton R, Thornsberry C, Karlowsky J, Sahm D. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn Microbiol Infect Dis 2003; 47:579-86.
11. Kristinsson KG. Mathematical models as tools for evaluating the effectiveness of interventions. Clin Infect Dis 2001; 33(Suppl 3):S174-9.
12. Thornsberry C. Antimicrobial resistance: yesterday, today and tomorrow [abstract 217C]. In: Program and abstracts of the 103rd General Meeting of the American Society for Microbiology. Washington, DC: American Society for Microbiology, 2003:167.
13. Resistance surveillance: local hotspots, global strategies: a focus on common RTI pathogens. A GlaxoSmithKline-sponsored symposium presented at the 2004 European Congress of Clinical Microbiology and Infectious Diseases (Prage, Czech Republic). Clin Microbiol Infect 2004; 10(Suppl 3):24-6.